Chemomab Therapeutics Ltd - ADR Stock

$1.39

0.00% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US16385C1045

Symbol

CMMB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Chemomab Therapeutics Ltd - ADR Stock price

$1.39

-13.49 90.66% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.00 0.00%

ISIN

US16385C1045

Symbol

CMMB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$26.22m
Enterprise Value	$15.81m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	2.52
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-14.18m
Cash position	$10.70m
EPS (TTM) EPS	$-0.76
P/E forward	negative
Short interest	0.65%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Chemomab Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Chemomab Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	0.03 0.03	40% 40% -
Gross Profit	- -	- -
- Selling and Administrative Expenses	3.51 3.51	39% 39% -
- Research and Development Expense	11 11	27% 27% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-14 -14	31% 31% -
Net Profit	-13 -13	31% 31% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Chemomab Therapeutics Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

6 days ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

— Reported Positive 48-Week Data from SPRING Trial — Nebokitug Treatment in PSC P atients with M oderate/ A dvanced D isease R esulted in C ontinued I mprovements across K ey B iomarkers of Li ver I njury, I nflammation and Fi brosis — — Align ed with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with a Single, Clinical-Events-Driven Clinical Trial— — Th e se Major Mi...

Neutral

GlobeNewsWire

●

16 days ago

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of Disease Progression Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 T...

Neutral

GlobeNewsWire

●

23 days ago

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Chemomab reported new clinical data to be presented at EASL 2025 that further confirms the potential of nebokitug as a first-in-class treatment for PSC.

More Chemomab Therapeutics Ltd - ADR News

Company Profile

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

Head office	United States
CEO	Adi Mor
Employees	16
Founded	2011
Website	www.chemomab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now